Sun gets favourable ruling in battle for Taro
Late in the day The Tel-Aviv District Court told Taro's directors that it was "disingenuous" to claim now, over a year after they approved the transaction, that a special tender offer was required. Our Bureau Mumbai, Aug. 27 Sun Pharma's $454-million proposal to acquire Israeli-drug company Taro Pharmaceutical received a shot in the arm, with the Tel-Aviv District Court rejecting Taro's contention that Sun should conduct a 'special tender offer' under the Israeli law. Consequently, Sun Pharma will be able to complete its previously announced tender offer by its subsidiary, Alkaloida Chemical Company Exclusive Group Ltd, a Sun Pharma communiqué said. However, the course is only partially clear, as Taro could appeal the ruling, following which the case could then shift to Israel's Supreme Court, a company official familiar with the development told Business Line . Taro had terminated Sun's acquisition proposal, a year after